Get the Stockscreener App
85.40
1.43%
1.20
Protagonist Therapeutics Inc stock is traded at $85.40, with a volume of 906.11K.
It is up +1.43% in the last 24 hours and up +13.87% over the past month.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
See More
Previous Close:
$84.20
Open:
$84.24
24h Volume:
906.11K
Relative Volume:
0.78
Market Cap:
$5.34B
Revenue:
$209.18M
Net Income/Loss:
$52.04M
P/E Ratio:
119.86
EPS:
0.7125
Net Cash Flow:
$37.10M
1W Performance:
+0.93%
1M Performance:
+13.87%
6M Performance:
+86.38%
1Y Performance:
+105.04%
1-Day Range:
$83.64
$86.67
1-Week Range:
$82.79
$86.95
52-Week Range:
$33.70
$93.25
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics Inc
Sector
Industry
Phone
(510) 474-0170
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
85.40 | 5.26B | 209.18M | 52.04M | 37.10M | 0.7125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-12-25 | Initiated | Leerink Partners | Outperform |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-06-24 | Initiated | Goldman | Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Sep-24-24 | Initiated | TD Cowen | Buy |
| Sep-09-24 | Initiated | Truist | Buy |
| Oct-30-23 | Initiated | CapitalOne | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Aug-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Oct-12-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-11-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Sep-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-21 | Initiated | JMP Securities | Mkt Outperform |
| May-24-21 | Initiated | Northland Capital | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Dec-16-20 | Initiated | Piper Sandler | Overweight |
| Sep-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Initiated | Jefferies | Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| May-09-19 | Upgrade | Stifel | Hold → Buy |
| Dec-06-18 | Initiated | Nomura | Buy |
| Jan-29-18 | Initiated | Stifel | Buy |
| Jul-21-17 | Initiated | BTIG Research | Buy |
View All
Protagonist Therapeutics Inc Stock (PTGX) Latest News
Intech Investment Management LLC Acquires 2,971 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill - Times Herald
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting - Daily American
Envestnet Asset Management Inc. Grows Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics stock maintains Buy rating at Jefferies on pipeline potential - Investing.com Canada
What hedge fund activity signals for Protagonist Therapeutics Inc. stockWall Street Watch & Real-Time Chart Breakout Alerts - newser.com
How rising interest rates impact Protagonist Therapeutics Inc. stockRate Hike & Entry Point Strategy Guides - newser.com
How Protagonist Therapeutics Inc. stock responds to policy changesTrade Risk Summary & Weekly Top Gainers Trade List - newser.com
Is Protagonist Therapeutics Inc. stock entering bullish territoryCPI Data & Advanced Technical Analysis Signals - newser.com
What risks investors should watch in Protagonist Therapeutics Inc. stockEarnings Recap Report & Daily Oversold Stock Bounce Ideas - newser.com
Is Protagonist Therapeutics Inc. stock cheap compared to fundamentalsMarket Growth Summary & Weekly Top Gainers Trade List - newser.com
Protagonist Therapeutics (PTGX) Price Target Increased by 16.48% to 91.65 - MSN
Protagonist Therapeutics expands scope of peptide therapeutics - Traders Union
Protagonist Therapeutics, Inc. $PTGX is Knott David M Jr's 9th Largest Position - MarketBeat
Protagonist Therapeutics Opens with 27.21% Gain Amidst Market Decline - Markets Mojo
Persistent Asset Partners Ltd Takes Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by Bank of New York Mellon Corp - MarketBeat
H.C. Wainwright Reaffirms Their Buy Rating on Protagonist Therapeutics (PTGX) - The Globe and Mail
How Protagonist Therapeutics Inc. stock reacts to job market dataMarket Movement Recap & AI Powered Market Entry Strategies - newser.com
Protagonist Therapeutics, Inc. $PTGX Stock Holdings Trimmed by Aviva PLC - MarketBeat
November 2025's Top Value Picks For Potential Market Opportunities - Yahoo Finance
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by Jupiter Asset Management Ltd. - MarketBeat
Protagonist Therapeutics Inc. stock chart pattern explained2025 Trading Recap & Reliable Volume Spike Trade Alerts - newser.com
135,050 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Nan Fung Trinity HK Ltd. - MarketBeat
Profund Advisors LLC Has $1.05 Million Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
We Think You Can Look Beyond Protagonist Therapeutics' (NASDAQ:PTGX) Lackluster Earnings - 富途牛牛
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Central New Jersey News
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences - York Daily Record
How strong is Protagonist Therapeutics Inc. stock revenue growthEarnings Trend Report & Daily Profit Maximizing Tips - newser.com
Protagonist Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Market Performance - Markets Mojo
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $98.00 at Citigroup - MarketBeat
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Morris County NJ News | Daily Record
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress - Tallahassee Democrat
Citigroup Maintains Protagonist Therapeutics (PTGX) Buy Recommendation - Nasdaq
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Protagonist Therapeutics Inc Stock (PTGX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Waddill William D. | Director |
Oct 10 '25 |
Option Exercise |
6.98 |
12,000 |
83,760 |
17,130 |
| Waddill William D. | Director |
Oct 10 '25 |
Sale |
81.62 |
12,000 |
979,480 |
5,130 |
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):